Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Screener

ANL

Adlai Nortye Ltd. ADR

May 24 • 04:00PM ET

10.50

Dollar change -1.53
Percentage change -12.72	%

Healthcare • Biotechnology • China • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	93.71M	Perf Week	-24.46%
Market Cap	983.95M	Forward P/E	-	EPS next Y	-3.79	Insider Trans	-	Shs Float	-	Perf Month	-15.73%
Income	-	PEG	-	EPS next Q	-	Inst Own	0.06%	Short Float	-	Perf Quarter	44.83%
Sales	-	P/S	-	EPS this Y	66.80%	Inst Trans	-	Short Ratio	1.36	Perf Half Y	28.83%
Book/sh	-3.35	P/B	-	EPS next Y	-57.26%	ROA	-	Short Interest	0.01M	Perf Year	-
Cash/sh	0.64	P/C	16.39	EPS next 5Y	-	ROE	-	52W Range	7.11 - 19.30	Perf YTD	16.80%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-90.91%	ROI	-	52W High	-45.60%	Beta	-
Dividend TTM	-	Quick Ratio	0.16	Sales past 5Y	-25.00%	Gross Margin	-	52W Low	47.65%	ATR (14)	1.41
Dividend Ex-Date	Aug 13, 2008	Current Ratio	0.16	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	38.12	Volatility	10.75% 10.54%
Employees	-	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	30.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-	Payout	-	Rel Volume	2.00	Prev Close	12.03
Sales Surprise	0.00%	EPS Surprise	-150.34%	Sales Q/Q	-	Earnings	-	Avg Volume	8.87K	Price	10.50
SMA20	-21.39%	SMA50	-7.74%	SMA200	4.40%	Trades		Volume	17,703	Change	-12.72%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$30

May-23-24 09:03PM	Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024 (GlobeNewswire) -5.65%
May-22-24 08:00AM	Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy (GlobeNewswire)
May-15-24 09:40AM	Are Medical Stocks Lagging Adlai Nortye Ltd. Sponsored ADR (ANL) This Year? (Zacks) +7.08%
Apr-25-24 09:40AM	Is Adlai Nortye Ltd. Sponsored ADR (ANL) Stock Outpacing Its Medical Peers This Year? (Zacks)
Mar-29-24 06:00AM	Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development (GlobeNewswire)
07:30AM	Loading…
Nov-17-23 07:30AM	Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC (GlobeNewswire)
Oct-23-23 08:12AM	Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award (GlobeNewswire)
Oct-03-23 12:05PM	Adlai Nortye Ltd. Announces Closing of Initial Public Offering (GlobeNewswire) -6.87%
Sep-29-23 02:46AM	Adlai Nortye Ltd. Announces Pricing of Initial Public Offering (GlobeNewswire)

Adlai Nortye Ltd. operates as a clinical-stage biopharmaceutical company focused on the development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018 and is headquartered in Hangzhou, China.

ANL

Adlai Nortye Ltd. ADR

Upgrade your FINVIZ experience